Krystal Biotech Stock
Price
Target price
€148.15
€148.15
-1.560%
-2.35
-1.560%
€179.60
04.06.24 / Tradegate
WKN: A2JH2F / Symbol: KRYS / Name: Krystal Biotech / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Krystal Biotech Stock
A loss of -1.560% shows a downward development for Krystal Biotech.
Krystal Biotech is currently one of the favorites of our community with 18 Buy predictions and no Sell predictions.
With a target price of 179 € there is a positive potential of 20.82% for Krystal Biotech compared to the current price of 148.15 €.
So far the community has only identified positive things for Krystal Biotech stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Krystal Biotech in the next few years
Pros
?
B****
?
G***** c******* t* c**********
?
S********** s********
Cons
?
M***** P*******
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Krystal Biotech vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Krystal Biotech | -1.560% | 1.230% | 1.786% | 25.551% | 27.716% | - | - |
Ardelyx Inc. | -4.700% | -0.961% | -27.326% | 77.249% | 7.024% | 11.459% | - |
Evolus Inc | -0.870% | -0.870% | -6.557% | 41.615% | 25.967% | 27.374% | - |
Salarius Pharmaceuticals Inc. | -3.540% | -1.036% | -10.329% | -71.061% | -31.171% | -98.433% | -99.994% |
Comments
Krystal Biotech, Inc. (NASDAQ: KRYS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $200.00 price target on the stock.
Show more
Ratings data for KRYS provided by MarketBeat
Krystal Biotech, Inc. (NASDAQ: KRYS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $200.00 price target on the stock.
Show more
Ratings data for KRYS provided by MarketBeat
Krystal Biotech, Inc. (NASDAQ: KRYS) had its "buy" rating re-affirmed by analysts at Stifel Nicolaus. They now have a $204.00 price target on the stock, up previously from $178.00.
Show more
Ratings data for KRYS provided by MarketBeat